deafness88
New Member
- Joined
- Jun 26, 2004
- Messages
- 54
- Reaction score
- 0
Sound Pharmaceuticals Begins Phase II Clinical Testing of SPI-1005 for NIHL
SPI-1005 mimics glutathione peroxidase -- an enzyme that reduces metabolic stress in the cochlea -- and encourages genes to make more of it. If the drug earns regulatory approval, the defense department and the veterans affairs agency could be big customers. Phase II trials in noise-induced hearing loss will be completed by midyear, and Phase III studies could commence later this year or in early 2009
Now, it is close to finding out if the compound can help people who have lost their hearing. Getting this far has not been easy. "It's been almost six years from idea to a Phase II," Kil said. "Once Sound shows some positive Phase II data, the tide will turn."
SPI-1005 mimics glutathione peroxidase -- an enzyme that reduces metabolic stress in the cochlea -- and encourages genes to make more of it. If the drug earns regulatory approval, the defense department and the veterans affairs agency could be big customers. Phase II trials in noise-induced hearing loss will be completed by midyear, and Phase III studies could commence later this year or in early 2009
Now, it is close to finding out if the compound can help people who have lost their hearing. Getting this far has not been easy. "It's been almost six years from idea to a Phase II," Kil said. "Once Sound shows some positive Phase II data, the tide will turn."